Laidlaw Downgrades Mast Therapeutics (MSTX) to Neutral
- Wall St. gains across sectors ahead of Trump inauguration
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Herbalife (HLF) Says SEC Requested Documents on Anti-Corruption Compliance in China; Reviewed with DoJ
- Investment Focus: History suggests Trump month will be stocks down, dollar up
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Laidlaw downgraded Mast Therapeutics (NYSE: MSTX) from Buy to Neutral.
Shares of Mast Therapeutics closed at $0.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: SunTrust Robinson Humphrey Downgrades Health Care REIT (HCN) to Hold
- UPDATE: SunTrust Robinson Humphrey Downgrades Corporate Office Properties Trust (OFC) to Hold
- BofA/Merrill Lynch Downgrades Allegheny Technologies (ATI) to Underperform
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!